[unable to retrieve full-text content]
Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial NasdaqCAMBRIDGE, Mass., Jan. 07, 2019-- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying,.
Read Again https://www.nasdaq.com/press-release/spero-therapeutics-signs-license-agreement-with-everest-medicines-to-develop-manufacture-and-20190107-01198Bagikan Berita Ini
0 Response to "Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial - Nasdaq"
Post a Comment